These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32462834)

  • 1. [A new hope in the treatment of hepatocellular carcinoma].
    Thouvenin L; Friedlaender A
    Rev Med Suisse; 2020 May; 16(695):1074-1078. PubMed ID: 32462834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic treatment options of primary hepatocellular carcinoma].
    Dank M; Padányi P
    Magy Onkol; 2018 Mar; 62(1):53-61. PubMed ID: 29570187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment of advanced hepatocellular cancer: new hope on the horizon.
    Chang Lee R; Tebbutt N
    Expert Rev Anticancer Ther; 2019 Apr; 19(4):343-353. PubMed ID: 30793991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
    Boland P; Wu J
    Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies.
    Liu PH; Huo TI; Miksad RA
    Semin Liver Dis; 2018 Aug; 38(3):242-251. PubMed ID: 30041276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: From diagnosis to treatment.
    Grandhi MS; Kim AK; Ronnekleiv-Kelly SM; Kamel IR; Ghasebeh MA; Pawlik TM
    Surg Oncol; 2016 Jun; 25(2):74-85. PubMed ID: 27312032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
    Ogasawara S; Chiba T; Ooka Y; Suzuki E; Maeda T; Yokoyama M; Wakamatsu T; Inoue M; Saito T; Kobayashi K; Kiyono S; Nakamura M; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N
    Invest New Drugs; 2018 Apr; 36(2):332-339. PubMed ID: 28891038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib: a promising treatment for hepatocellular carcinoma.
    Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
    Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges of advanced hepatocellular carcinoma.
    Colagrande S; Inghilesi AL; Aburas S; Taliani GG; Nardi C; Marra F
    World J Gastroenterol; 2016 Sep; 22(34):7645-59. PubMed ID: 27678348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
    Witjes CD; Verhoef C; Verheul HM; Eskens FA
    Neth J Med; 2009 Mar; 67(3):86-90. PubMed ID: 19307678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
    Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
    BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
    Lai JM; Hu S; Lin H; Luo H; Luo YB
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
    Yegin EG; Oymaci E; Karatay E; Coker A
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of advanced hepatocellular carcinoma : Novel agents and role of local therapy].
    Parisod L; Duran R; Denys A; Digklia A
    Rev Med Suisse; 2017 May; 13(563):1032-1034. PubMed ID: 28636293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside.
    Abdel-Rahman O
    J Egypt Natl Canc Inst; 2013 Dec; 25(4):165-71. PubMed ID: 24207088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Management of Hepatocellular Carcinoma.
    Rich NE; Yopp AC; Singal AG
    J Oncol Pract; 2017 Jun; 13(6):356-364. PubMed ID: 28605614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.